Skip to main content
Have a personal or library account? Click to login
Comparing the diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI for detecting bone metastases in breast cancer: a meta-analysis Cover

Comparing the diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI for detecting bone metastases in breast cancer: a meta-analysis

Radiology and Oncology
Volume 57 (2023): Issue 3 (September 2023)
By: Longjie Xia,  Jianqin Lai,  Di Huang,  Shenghui Qiu,  Huiqiong Hu,  Yunxiang Luo and  Jie Cao  
Open Access
|Jul 2023
Figures & tables

Figures & Tables

FIGURE 1.

PRISMA flow diagram illustrating the study selection process.FN = false negative; FP = false positive; TN = true negative; TP = true positive

FIGURE 2.

Risk of bias and applicability concerns of the included studies using the Quality Assessment of Diagnostic Performance Studies QUADAS-2 tool.

FIGURE 3.

Forest plot showing the pooled sensitivities of [18F]FDG PET/CT and [18F]FDG PET/MRI in bone metastasis of breast cancer patients on a patient-based analysis. The plot displays individual study estimates (squares) with corresponding 95% confidence intervals (horizontal lines) and the pooled sensitivity estimate (diamond) for both modalities. The size of the squares represents the relative weight of each study in the meta-analysis.9,15,17,18,21,23,25

FIGURE 4.

Forest plot showing the pooled sensitivities of [18F]FDG PET/CT and [18F]FDG PET/MRI in bone metastasis of breast cancer patients on a lesion-based analysis. The plot displays individual study estimates (squares) with corresponding 95% confidence intervals (horizontal lines) and the pooled sensitivity estimate (diamond) for both modalities. The size of the squares represents the relative weight of each study in the meta-analysis.9,10,11,18,19,20,22,23,24,25,26,27

FIGURE 5.

Forest plot showing the pooled specificities of [18F]FDG PET/CT and [18F]FDG PET/MRI in bone metastasis of breast cancer patients on a patient-based analysis. The plot displays individual study estimates (squares) with corresponding 95% confidence intervals (horizontal lines) and the pooled specificity estimate (diamond) for both modalities. The size of the squares represents the relative weight of each study in the meta-analysis.9,15,17,18,21,23,25

FIGURE 6.

Forest plot showing the pooled specificities of [18F]FDG PET/CT and [18F]FDG PET/MRI in bone metastasis of breast cancer patients on a lesion-based analysis. The plot displays individual study estimates (squares) with corresponding 95% confidence intervals (horizontal lines) and the pooled specificity estimate (diamond) for both modalities. The size of the squares represents the relative weight of each study in the meta-analysis.9,18,19,20,21,23,25,26,27

Study and patient characteristics of the included studies for [18F]FDG PET/CT

AuthorYearType of imaging testStudy characteristicsPatient characteristics
CountryStudy designAnalysisReference standardNo. of patientsClinical indicationMean/Median agePrevious treatment
Catalano et al.152015PET/CTItalyRetroPBPathology and/or follow-up imaging109Initial stage and post-treatment stageMean ± SD: (58.08 ± 10.7)Surgery
Melsaether et al.102016PET/CTUSAProLBPathology and/or follow-up imaging51Initial stage and post-treatment stageMean(range): 56 (32–76)Chemotherapy
Botsikas et al.92018PET/CTSwitzerlandProPB and LBPathology and/or follow-up imaging80Initial stage and post-treatment stageMean ± SD: (48 ± 12.9)NA
Sawicki et al.112016PET/CTGermanyProLBPathology and/or follow-up imaging21Post-treatment stageMean ± SD: (59.4 ±11.5)NA
Balci et al.172012PET/CTTurkeyRetroPBPathology and/or follow-up imaging162Initial stage and post-treatment stageMean: 50.6Surgery
Hahn et al.182011PET/CTGermanyRetroPB and LBFollow-up imaging29Initial stageMean (range): 57.5 (35–78)NA
Manohar et al.192012PET/CTIndiaRetroLBPathology and/or follow-up imaging111Post-treatment stageMean(range): 52 (22–80)Surgery
Niikura et al.252011PET/CTJapanRetroLBPathology and/or follow-up imaging225Initial stage and post-treatment stageMean: 53.4Chemotherapy or endocrine therapy
Riegger et al.222012PET/CTGermanyRetroLBPathology and/or follow-up imaging106Initial stageMean ± SD: (57 ± 13)NA
Rager et al.232018PET/CTSwitzerlandRetroPB and LBFollow-up imaging25Initial stage and post-treatment stageMedian(range): 5 (38–82)NA
Demir et al.202014PET/CTTurkeyRetroLBPathology and/or follow-up imaging50Post-treatment stageMean ± SD: (53.9 ± 12.3)NA
Hansen et al.242015PET/CTDenmarkProLBPathology18Post-treatment stageMean(range): 61.5 (38–76)Surgery
Niikura et al.212016PET/CTJapanProPBPathology and/or follow-up imaging28Initial stage and post-treatment stageMedian(range): 59 (31–76)Surgery
Shawky et al.262016PET/CTEgyptProLBPathology and/or follow-up imaging30Post-treatment stageMean(range): 53.5 (33–73)Surgery or Chemotherapy or radiotherapy
Teke et al.272020PET/CTTurkeyRetroLBFollow-up imaging62Initial stageMedian(range): 44.5 (8–81)NO

Study and patient characteristics of the included studies for [18F]FDG PET/MRI

AuthorYearType of imaging testStudy characteristicsPatient characteristics
CountryStudy designAnalysisReference standardNo. of patientsClinical indicationMean/Median agePrevious treatment
Catalano et al.152015PET/MRIItalyRetroPBPathology and/or follow-up imaging109Initial stage and post-treatment stageMean ± SD: (58.08 ± 10.7)Surgery
Bruckmann et al.212021PET/MRIGermanyProPB and LBPathology154Post-treatment stageMean ± SD: (53.8±11.9)NO
Melsaether et al.102016PET/MRIUSAProLBPathology and/or follow-up imaging51Initial stage and post-treatment stageMean(range): 56(32–76)Chemotherapy
Botsikas et al.92018PET/MRISwitzerlandProPB and LBPathology and/or follow-up imaging80Initial stage and post-treatment stageMean ± SD: (48 ± 12.9)NA
Sawicki et al.112016PET/MRIGermanyProLBPathology and/or follow-up imaging21Post-treatment stageMean ± SD: (59.4 ± 11.5)NA
DOI: https://doi.org/10.2478/raon-2023-0037 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 299 - 309
Submitted on: Apr 1, 2023
Accepted on: Jun 15, 2023
Published on: Jul 26, 2023
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
[18F]FDG PET/CT,
[18F]FDG PET/MRI,
bone metastases,
breast cancer,
meta-analysis
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2023 Longjie Xia, Jianqin Lai, Di Huang, Shenghui Qiu, Huiqiong Hu, Yunxiang Luo, Jie Cao, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 57 (2023): Issue 3 (September 2023)
Previous article
Next article